Open notebook, pencil, glasses, a glass of water and a eucalyptus sprig on a light wooden table

Medicines for weight management: what's available and how they work

In short

Only a few active substances are approved for weight management. Most are prescription-only and meant for adults with obesity, or overweight with related conditions, alongside diet and exercise.

Over-the-counter “slimming” products mostly have thin evidence. Which medicine is suitable is a medical decision.

GLP-1 medicines

Semaglutide, tirzepatide and liraglutide mimic gut hormones that signal fullness and slow stomach emptying. Tirzepatide also acts on the GIP receptor. They're mostly given as injections, daily or weekly; semaglutide is also available as a tablet.

They're the best-studied group in this area. The most common side effects are gastrointestinal, especially during titration. Whether and how a switch or a dose change happens is decided by the doctor in each individual case.

Other approved medicines

Orlistat blocks an enzyme in the gut that breaks down fat, so part of dietary fat passes through undigested. Oily stools and diarrhoea are typical, especially after fatty meals. A lower-dose version is available over the counter in pharmacies.

The combination of naltrexone and bupropion acts on appetite and reward centres in the brain. It's prescription-only and has its own contraindications, for example certain mental health conditions or high blood pressure.

Over-the-counter products and supplements

Fibre supplements, fat binders, “metabolism boosters” and slimming patches are widely advertised. For most there's no or only weak evidence of a meaningful effect. Fibre can support fullness but doesn't replace treatment.

Be careful with online products promising “fast weight loss”: they can contain undeclared, sometimes dangerous substances.

Who medicines are meant for

Prescription weight-management medicines are usually approved for adults with a BMI of 30 or more, or 27 or more with a weight-related condition. They're meant as an addition, not a replacement for diet, movement and sleep.

Whether a medicine is an option for you is assessed in the medical review of your questionnaire.

Frequently asked questions

Note

This Journal article offers general information. It is not a diagnosis, a prescription or a promise of any result. Whether treatment is suitable for you is decided by a doctor after reviewing your questionnaire. For acute or severe symptoms, contact your GP, the out-of-hours medical service (116117) or, in an emergency, 112. Whether and how a switch or a dose change happens is decided by the doctor in each individual case.

Sources and medical review

Based on European Medicines Agency product information and the German S3 guideline on obesity prevention and treatment. Educational only; does not replace an individual medical decision. Medical review pending.

  • European Medicines Agency product information for semaglutide, tirzepatide, liraglutide, orlistat and naltrexone/bupropion
  • German S3 guideline on prevention and treatment of obesity (German Obesity Society)